Product Description
JNJ-64457744 is an oral drug candidate being developed by Janssen Research & Development. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05423106?term=JNJ-64457744&draw=2&rank=1)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Johnson & Johnson
Company Location: Eastern America
Company CEO: Joaquin Duato
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Hepatitis B, Chronic
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05423106 |
CR109208 | P1 |
Terminated |
Hepatitis B, Chronic |
2023-03-14 |
23% |
2023-06-09 |
Recent News Events
Date |
Type |
Title |
|---|